(Theme 2) COVID-19 Pulmozyme clinical trial plan

Building on existing work microbial sepsis, researchers are designing clinical trials to test the efficacy of monoclonal antibody-mediated and biological therapy for cytokine-induced severe COVID disease, with promising results. Similarly, as histones are highly pro-inflammatory and become a central driver of these cytokines researchers at the Crick have initiated a human trial to treat COVID-19 with anti-histone Pulmozyme (DNase I). In parallel, studies of systemic fungal infection which share the major pathogenic mechanisms with virus induced sepsis may also have links not only with the cytokine storm but importantly with immune dysfunction whose origins remain unknown.